• Fangchinoline Restores Lysosomal Defense Against H1N1

  2026-10-07

  The reference study identifies fangchinoline as a host-directed antiviral candidate that restores TFEB-associated lysosomal programs and interferes with H1N1 entry. Its integrated screening, transcriptomic, organelle, time-resolved infection, and in vivo evidence supports lysosomal function as a potential influenza research target, while leaving important questions about specificity, safety, and clinical translation unresolved.

• HyperScribe™ mRNA Kit: Evidence and Limits

  2026-10-07

  The HyperScribe™ mRNA synthesis kit is described here as a research reagent for producing capped, polyadenylated, nucleoside-modified mRNA, not as a CAR-T therapy. The cited mouse study supports in vivo CD19 CAR-T generation with targeted lipid nanoparticles, but it does not establish that K1068 was used or that the kit reproduces those findings.

• Selective Nanomolar IRAP Inhibitors from Bestatin

  2026-10-06

  The reference study develops α-hydroxy-β-amino acid derivatives of bestatin as selective inhibitors of insulin-regulated aminopeptidase (IRAP). By combining stereochemically controlled scaffold functionalization, biochemical profiling, cellular testing, and X-ray crystallography, the authors identify a low-nanomolar, cell-active IRAP inhibitor and link selectivity to interactions involving the GAMEN loop.

• Firefly Luciferase mRNA: An Interpretability-First Guide

  2026-10-06

  Firefly Luciferase mRNA (ARCA, 5-moUTP) is examined as more than a luminescent readout: it is a tool for separating delivery, translation, and measurement effects. This evidence-focused guide connects reporter interpretation with recent findings on pH-responsive lipid nanoparticles while defining the product’s applicability boundaries.

• Cas9 mRNA in Fyn–STAT3 Neurodegeneration Research

  2026-10-05

  A source-grounded overview of how Cas9 mRNA may conceptually support functional gene studies related to Fyn–STAT3 signaling, while distinguishing supplier claims from findings reported in a zebrafish neurodegeneration study.

• EZ Cap Cy5 Firefly Luciferase mRNA: Beyond Signal

  2026-10-05

  EZ Cap Cy5 Firefly Luciferase mRNA combines Cy5-based RNA tracking with firefly luciferase expression, but its greatest value is interpretive: separating delivery, intracellular fate, and translation. This article applies that framework to findings from a 2024 vorinostat study while defining the evidence boundaries for 5-moUTP modified mRNA.

• 2-D08 and the Next Phase of SUMO Biology

  2026-10-04

  2-D08 (2’,3’,4’-trihydroxyflavone) offers a mechanistically distinct way to interrogate SUMO transfer, while emerging work on the ETS1–SENP2–HSPA8–FUNDC1 axis shows why SUMO biology matters beyond oncology. This perspective connects reported findings with translational questions, evidence boundaries, and the next generation of validation strategies.

• Cy3 Rabbit Anti-Goat IgG (H+L) Overview

  2026-10-03

  Cy3 Rabbit Anti-Goat IgG (H+L) Antibody, SKU K1215, is a Cy3-conjugated secondary antibody described by APExBIO for fluorescent detection of goat IgG. No matched peer-reviewed paper evidence was provided, so performance claims remain supplier-reported.

• Nicotinamide Riboside Chloride in RGC Research

  2026-10-02

  Use Nicotinamide Riboside Chloride (NIAGEN) as a controlled metabolic variable alongside a chemically defined retinal ganglion cell differentiation workflow. This approach separates lineage instruction from NAD+ biology, enabling clearer studies of oxidative metabolism modulation, cell stress, and neurodegenerative disease phenotypes.

• Conserved-RBD mRNA Vaccine for Omicron and SARS-CoV

  2026-10-01

  Guan et al. engineered a lipid nanoparticle mRNA vaccine that replaces the mutation-prone Omicron RBD with a conserved, immunogenic SARS-CoV RBD while retaining the broader SARS-CoV-2 spike framework. In mice, this chimeric construct generated cross-reactive neutralizing antibodies and protection against both SARS-CoV-2 Omicron and SARS-CoV, providing a useful design model for broadly reactive mRNA vaccine development.

• SIRT1 Restores Mitochondrial Biogenesis in N2a Cells

  2026-10-01

  This 2024 study identifies a SIRT1–PGC-1α–TFAM pathway that links prion peptide toxicity to impaired mitochondrial biogenesis in N2a neuroblastoma cells. Its rescue experiments with SIRT1 activation and resveratrol support mitochondrial biogenesis as a mechanistic target, while also highlighting the limits of extrapolating cell-based findings to prion disease therapy.

• HyperScribe™ mRNA for In Vivo CAR-T Studies

  2026-09-30

  Explore how mRNA synthesis chemistry shapes in vivo CAR-T assay design, using the K1068 HyperScribe™ kit and recent CD19 CAR-T research as a framework for better controls, interpretation, and translation.

• PTH (1-34) Peptide in Kidney Assays

  2026-09-30

  Parathyroid hormone (1-34) (human) can serve as a calibrated perturbation for connecting receptor signaling with spatially organized kidney function. This article presents an assay-design framework for interpreting calcium, cAMP, epithelial, and bone-related responses in kidney assembloid and osteoporosis model research.

• R2 Retrotransposon Insertions and DNA Repair

  2026-09-29

  McIntyre, Horton, and Collins used the PRINT system to isolate the cellular events that stabilize first-strand cDNA after R2-mediated target-primed reverse transcription. Their results identify alternative ATR–Polymerase θ, 53BP1–Shieldin/CST–Polα-primase, and CtIP–MRN-dependent repair routes that generate distinct insertion lengths and junction signatures.

• QX77 for Autophagy and Stem Cell Workflows

  2026-09-29

  QX77 is a molecular chaperone activator for studying LAMP2A-linked chaperone-mediated autophagy, Rab11-dependent trafficking, and ES cell differentiation. This workflow-focused guide shows how to build dose–time screens, separate pathway activation from toxicity, and connect CMA experiments with emerging mitophagy research.

673 records 2/45 page Previous Next 12345 下5页 Last page